Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab

Eye (Basingstoke)

Volumn 27, Issue 5, 2013, Pages 663-668

  Patel, K H ^a   Chow, C C ^a   Rathod, R ^a   Mieler, W F ^a   Lim, J I ^a   Ulanski, L J ^a   Leiderman, Y I ^a   Arun, V ^b   Chau, F Y ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University Ophthalmology   (United States)

Author keywords

aflibercept; age related macular degeneration; retinal pigment epithelial detachment

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TACHYPHYLAXIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 84877665569     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.31     Document Type: Article

References (13)

1. Coscas F, Coscas G, Souied E, Tick S, Soubrane G. Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2007; 144(4): 592-599.
2. Pepple K, Mruthyunjaya P. Retinal pigment epithelial detachments in age-related macular degeneration: classification and therapeutic options. Semin Ophthalmol 2011; 26(3): 198-208.
3. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in agerelated macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109(9): 1220-1231.
4. Arias L. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clin Ophthalmol 2010; 4: 369-374.
5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431.
6. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. ANCHOR Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-1444.
7. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012; 13(4): 585-591.
8. Pauleikhoff D, Loffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002; 240(7): 533-538.
9. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009; 148(1): 70-78.
10. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance Br J Ophthalmol 2012; 96(1): 1-2
11. Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012; 96(1): 21-23.
12. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009; 29(6): 723-731.
13. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012; 96(1): 14-20.